<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04293510</url>
  </required_header>
  <id_info>
    <org_study_id>EKNL</org_study_id>
    <nct_id>NCT04293510</nct_id>
  </id_info>
  <brief_title>Evaluation of Janus Kinase_3 in Juvenile Onset Systemic Lupus Erythematosus</brief_title>
  <official_title>Evaluation of Janus Kinase_3 Expression in Juvenile Onset Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the best understood mechanisms by which cytokines activate signals, thus eliciting
      specific responses in target cells, involves enzymes such as Janus kinases (JAKs) and
      transcriptional factors such as signal transducers and activators of transcription (STATs).
      For immune mediated diseases, both activating and inactivating mutations of JAKs and STATs
      may cause abnormalities in immune homeostasis. Polymorphisms of JAK/STAT genes have been
      linked to susceptibility for rheumatoid arthritis (RA) , systemic lupus erythematosus (SLE),
      psoriatic arthritis (PA) and inflammatory bowel disease (IBD) .

      Janus_kinase 3 expression will be evaluated in the serum and renal tissue of lupus patients
      during active stage of the disease through this study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will assess the relationship between the expression of Janus_kinase 3 and the
      clinical and laboratory parameters of disease activity . Disease activity will be assessed
      through the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Also, investigators
      will evaluate the relationship between Janus_ kinase 3 expression and histopathological
      classes of lupus nephritis according to the 2003 International Society of Nephrology/ Renal
      Pathology Society (ISN/RPS) classification of lupus nephritis. This will be done through
      Janus_kinase 3 assessment in the blood and renal tissue of lupus patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">July 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Janus-kinase 3 expression</measure>
    <time_frame>within 2 years</time_frame>
    <description>evaluation of Janus-kinase 3 expression in blood and renal tissue of lupus patients during active stage of disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation</measure>
    <time_frame>2 years</time_frame>
    <description>relationship between Janus- kinase expression and clinical and laboratory parameters of disease activity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>correlation</measure>
    <time_frame>2 years</time_frame>
    <description>relationship between Janus-kinase 3 expression and histopathological classification of renal biopsy in lupus nephritis proven patients</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>group study 1</arm_group_label>
    <description>children and adolescents who diagnosed as lupus patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group study 2</arm_group_label>
    <description>age and sex matched healthy children free from any infection with no family history of immunological diseases</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>renal biopsy and blood sampling</intervention_name>
    <description>renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3</description>
    <arm_group_label>group study 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      frozen renal tissue and whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This will include children and adolescents who fulfill the 2012 Systemic Lupus
        International Collaborating Clinics (SLICC) classification criteria of systemic lupus
        erythromatosus during a period of 2 years.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age younger than 16 years.

               -  Active disease stage

               -  Patients with biopsy proven lupus nephritis according to ISN/RPS classification
                  criteria of lupus nephritis

        Exclusion Criteria:

          -  Lupus patients in remission.

               -  Lupus patients with end stage renal disease.

               -  Lupus patients with secondary thrombotic thrombocytopenic purpura (TTP) and
                  hemolytic uremic syndrome (HUS).

               -  patients with moderate or severe infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Enas Mohamed Sayed Ahmed</last_name>
    <phone>01004870406</phone>
    <email>enasmhmd05@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol. 2004;5(12):253. Epub 2004 Nov 30. Review.</citation>
    <PMID>15575979</PMID>
  </reference>
  <reference>
    <citation>Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker PI, Le JM, Lee HS, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA, Seldin MF, Kastner DL, Gregersen PK. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007 Sep 6;357(10):977-86.</citation>
    <PMID>17804842</PMID>
  </reference>
  <reference>
    <citation>Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004 Feb;15(2):241-50. Erratum in: J Am Soc Nephrol. 2004 Mar;15(3):835-6.</citation>
    <PMID>14747370</PMID>
  </reference>
  <reference>
    <citation>Petri M. Review of classification criteria for systemic lupus erythematosus. Rheum Dis Clin North Am. 2005 May;31(2):245-54, vi. Review.</citation>
    <PMID>15922144</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 29, 2020</study_first_submitted>
  <study_first_submitted_qc>February 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>enas mohamed sayed ahmed</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Janus-kinase3</keyword>
  <keyword>active</keyword>
  <keyword>lupus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

